2010/3016(RSP) | [ParlTrack]

download json

2010/3016(RSP) Resolution on the Tuberculosis Vaccine Initiative (TBVI) - practical implementation of the Europe 2020 strategy with a view to meeting MDG 6 and eliminating tuberculosis by 2050

Progress: Procedure completed

Legal Basis:

RoP 136-p5

Subjects

Events

2011/06/17

EC - Commission response to text adopted in plenary

Documents

SP(2011)3791

2011/02/03

EP - Results of vote in Parliament

Documents

Results of vote in Parliament

2011/02/03

EP - Decision by Parliament

Details

Following the debate which took place during the sitting of 2 February 2011, the European Parliament adopted by 578 votes to 9 with 52 abstentions a resolution on the Tuberculosis Vaccine Initiative (TBVI) – practical implementation of the Europe 2020 strategy with a view to meeting MDG 6 and eliminating tuberculosis by 2050.

The resolution had been tabled by the EPP, ALDE, S&D, ECR and Greens/ALE groups.

It notes that with four years to go until the MDG deadline, the incidence of tuberculosis remains one of the main causes of death in the world, with nearly 2 million people dying as a result of the disease every year. Members underline the fact that only a vaccination programme involving a large-scale vaccination campaign could have a positive impact in terms of achieving MDG 6 after 2015, and in particular the eradication of tuberculosis by 2050. They consider vaccines to be an essential means of combating tuberculosis, together with better – reliable, low-cost and soundly based – testing, as well as more effective diagnosis and treatment, and this implies a major shift in the focus of research and an increase in sustainable funding. Tuberculosis vaccination ought to be carried out as a priority in dispensaries and clinics in developing countries. Members call, accordingly, for public health care services to be restored, taking the view that EU assistance should, first and foremost, support developing countries’ internal efforts to build human, institutional and infrastructure capacity.

On the question of funding, Parliament notes that the objective is still to invest 3% of GDP in research and development in spite of budgetary constraints (COM(2010)2020 and COM(2010)0546), and it calls on the Commission to explore innovative funding channels , such as the establishment by the Member States and/or the Union of a financial guarantee to enable funding for the TBVI to be obtained from the European Investment Bank, with a view to securing finance for research in developing countries into neglected diseases and those involving little profit potential. Members point out that killer diseases such as tuberculosis ought to be the focus of a much greater pharmaceutical research effort, and insufficient research is currently being conducted into the most neglected diseases, which affect only people in developing countries. They call on the Commission and the Member States to stand by their funding commitments and do everything necessary to ensure that funds allocated to health care also reach the most impoverished people in developing countries, stressing the urgent need for public health services in the most remote areas.

Lastly, Parliament considers that the success of ‘vertical’ funds to tackle specific diseases such as Aids, malaria and tuberculosis must not mean a siphoning-off of resources from so-called ‘horizontal’ basic health care infrastructure. It stresses that an integrated approach, covering the various programmes targeted at specific diseases such as AIDS, malaria and tuberculosis together with a consolidation of basic health care systems, would enable the needs of people in developing countries to be addressed.

Documents

T7-0039/2011

2011/02/03

EP - End of procedure in Parliament

2011/02/02

EP - Oral question/interpellation by Parliament

Documents

B7-0006/2011

2011/02/02

EP - Debate in Parliament

Details

O-0203/2010

2011/01/26

EP - Motion for a resolution

Documents

B7-0075/2011

2011/01/26

EP - Motion for a resolution

Documents

B7-0076/2011

2011/01/26

EP - Motion for a resolution

Documents

B7-0086/2011

2011/01/26

EP - Motion for a resolution

Documents

B7-0089/2011

2011/01/26

Joint motion for resolution

Documents

RC-B7-0075/2011

Documents

Commission response to text adopted in plenary: SP(2011)3791
Results of vote in Parliament: Results of vote in Parliament
Decision by Parliament: T7-0039/2011
Oral question/interpellation by Parliament: B7-0006/2011
Motion for a resolution: B7-0075/2011
Motion for a resolution: B7-0076/2011
Motion for a resolution: B7-0086/2011
Motion for a resolution: B7-0089/2011
Joint motion for resolution: RC-B7-0075/2011
Motion for a resolution: B7-0075/2011
Motion for a resolution: B7-0076/2011
Motion for a resolution: B7-0086/2011
Motion for a resolution: B7-0089/2011
Joint motion for resolution: RC-B7-0075/2011
Oral question/interpellation by Parliament: B7-0006/2011
Commission response to text adopted in plenary: SP(2011)3791

Activities

Dagmar ROTH-BEHRENDT
Plenary Speeches (2)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)
Michael CASHMAN
Plenary Speeches (1)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)
Ricardo CORTÉS LASTRA
Plenary Speeches (1)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)
Filip KACZMAREK
Plenary Speeches (1)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)
Miroslav MIKOLÁŠIK
Plenary Speeches (1)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)
Joanna SENYSZYN
Plenary Speeches (1)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)
Csanád SZEGEDI
Plenary Speeches (1)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)
Claudiu Ciprian TĂNĂSESCU
Plenary Speeches (1)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)
Angelika WERTHMANN
Plenary Speeches (1)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)
Artur ZASADA
Plenary Speeches (1)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)
Anna ZÁBORSKÁ
Plenary Speeches (1)
- 2016/11/22 Tuberculosis Vaccine Initiative (debate)

History

(these mark the time of scraping, not the official date of the change)

2021-12-18Show (11) Changes | Timetravel

docs/0/docs/0/url	Old http://www.europarl.europa.eu/doceo/document/B-7-2011-0075_EN.html New https://www.europarl.europa.eu/doceo/document/B-7-2011-0075_EN.html
docs/1/docs/0/url	Old http://www.europarl.europa.eu/doceo/document/B-7-2011-0076_EN.html New https://www.europarl.europa.eu/doceo/document/B-7-2011-0076_EN.html
docs/2/docs/0/url	Old http://www.europarl.europa.eu/doceo/document/B-7-2011-0086_EN.html New https://www.europarl.europa.eu/doceo/document/B-7-2011-0086_EN.html
docs/3/docs/0/url	Old http://www.europarl.europa.eu/doceo/document/B-7-2011-0089_EN.html New https://www.europarl.europa.eu/doceo/document/B-7-2011-0089_EN.html
docs/4/docs/0/url	Old http://www.europarl.europa.eu/doceo/document/RC-7-2011-0075_EN.html New https://www.europarl.europa.eu/doceo/document/RC-7-2011-0075_EN.html
docs/5/docs/0/url	Old http://www.europarl.europa.eu/doceo/document/B-7-2011-0006_EN.html New https://www.europarl.europa.eu/doceo/document/B-7-2011-0006_EN.html
events/0/docs	url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20110202&type=CRE title: Debate in Parliament
events/2	date 2011-02-03T00:00:00 type Decision by Parliament body EP docs url: https://www.europarl.europa.eu/doceo/document/TA-7-2011-0039_EN.html title: T7-0039/2011 summary Following the debate which took place during the sitting of 2 February 2011, the European Parliament adopted by 578 votes to 9 with 52 abstentions a resolution on the Tuberculosis Vaccine Initiative (TBVI) – practical implementation of the Europe 2020 strategy with a view to meeting MDG 6 and eliminating tuberculosis by 2050. The resolution had been tabled by the EPP, ALDE, S&D, ECR and Greens/ALE groups. It notes that with four years to go until the MDG deadline, the incidence of tuberculosis remains one of the main causes of death in the world, with nearly 2 million people dying as a result of the disease every year. Members underline the fact that only a vaccination programme involving a large-scale vaccination campaign could have a positive impact in terms of achieving MDG 6 after 2015, and in particular the eradication of tuberculosis by 2050. They consider vaccines to be an essential means of combating tuberculosis, together with better – reliable, low-cost and soundly based – testing, as well as more effective diagnosis and treatment, and this implies a major shift in the focus of research and an increase in sustainable funding. Tuberculosis vaccination ought to be carried out as a priority in dispensaries and clinics in developing countries. Members call, accordingly, for public health care services to be restored, taking the view that EU assistance should, first and foremost, support developing countries’ internal efforts to build human, institutional and infrastructure capacity. On the question of funding, Parliament notes that the objective is still to invest 3% of GDP in research and development in spite of budgetary constraints (COM(2010)2020 and COM(2010)0546), and it calls on the Commission to explore innovative funding channels , such as the establishment by the Member States and/or the Union of a financial guarantee to enable funding for the TBVI to be obtained from the European Investment Bank, with a view to securing finance for research in developing countries into neglected diseases and those involving little profit potential. Members point out that killer diseases such as tuberculosis ought to be the focus of a much greater pharmaceutical research effort, and insufficient research is currently being conducted into the most neglected diseases, which affect only people in developing countries. They call on the Commission and the Member States to stand by their funding commitments and do everything necessary to ensure that funds allocated to health care also reach the most impoverished people in developing countries, stressing the urgent need for public health services in the most remote areas. Lastly, Parliament considers that the success of ‘vertical’ funds to tackle specific diseases such as Aids, malaria and tuberculosis must not mean a siphoning-off of resources from so-called ‘horizontal’ basic health care infrastructure. It stresses that an integrated approach, covering the various programmes targeted at specific diseases such as AIDS, malaria and tuberculosis together with a consolidation of basic health care systems, would enable the needs of people in developing countries to be addressed.
events/2	date 2011-02-03T00:00:00 type Decision by Parliament, 1st reading/single reading body EP docs url: http://www.europarl.europa.eu/doceo/document/TA-7-2011-0039_EN.html title: T7-0039/2011 summary Following the debate which took place during the sitting of 2 February 2011, the European Parliament adopted by 578 votes to 9 with 52 abstentions a resolution on the Tuberculosis Vaccine Initiative (TBVI) – practical implementation of the Europe 2020 strategy with a view to meeting MDG 6 and eliminating tuberculosis by 2050. The resolution had been tabled by the EPP, ALDE, S&D, ECR and Greens/ALE groups. It notes that with four years to go until the MDG deadline, the incidence of tuberculosis remains one of the main causes of death in the world, with nearly 2 million people dying as a result of the disease every year. Members underline the fact that only a vaccination programme involving a large-scale vaccination campaign could have a positive impact in terms of achieving MDG 6 after 2015, and in particular the eradication of tuberculosis by 2050. They consider vaccines to be an essential means of combating tuberculosis, together with better – reliable, low-cost and soundly based – testing, as well as more effective diagnosis and treatment, and this implies a major shift in the focus of research and an increase in sustainable funding. Tuberculosis vaccination ought to be carried out as a priority in dispensaries and clinics in developing countries. Members call, accordingly, for public health care services to be restored, taking the view that EU assistance should, first and foremost, support developing countries’ internal efforts to build human, institutional and infrastructure capacity. On the question of funding, Parliament notes that the objective is still to invest 3% of GDP in research and development in spite of budgetary constraints (COM(2010)2020 and COM(2010)0546), and it calls on the Commission to explore innovative funding channels , such as the establishment by the Member States and/or the Union of a financial guarantee to enable funding for the TBVI to be obtained from the European Investment Bank, with a view to securing finance for research in developing countries into neglected diseases and those involving little profit potential. Members point out that killer diseases such as tuberculosis ought to be the focus of a much greater pharmaceutical research effort, and insufficient research is currently being conducted into the most neglected diseases, which affect only people in developing countries. They call on the Commission and the Member States to stand by their funding commitments and do everything necessary to ensure that funds allocated to health care also reach the most impoverished people in developing countries, stressing the urgent need for public health services in the most remote areas. Lastly, Parliament considers that the success of ‘vertical’ funds to tackle specific diseases such as Aids, malaria and tuberculosis must not mean a siphoning-off of resources from so-called ‘horizontal’ basic health care infrastructure. It stresses that an integrated approach, covering the various programmes targeted at specific diseases such as AIDS, malaria and tuberculosis together with a consolidation of basic health care systems, would enable the needs of people in developing countries to be addressed.
procedure/legal_basis/0	Rules of Procedure EP 136-p5
procedure/legal_basis/0	Rules of Procedure EP 128-p5

2020-01-19Show (8) Changes | Timetravel

docs/0/docs/0/url	Old http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B7-2011-75&language=EN New http://www.europarl.europa.eu/doceo/document/B-7-2011-0075_EN.html
docs/1/docs/0/url	Old http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B7-2011-76&language=EN New http://www.europarl.europa.eu/doceo/document/B-7-2011-0076_EN.html
docs/2/docs/0/url	Old http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B7-2011-86&language=EN New http://www.europarl.europa.eu/doceo/document/B-7-2011-0086_EN.html
docs/3/docs/0/url	Old http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B7-2011-89&language=EN New http://www.europarl.europa.eu/doceo/document/B-7-2011-0089_EN.html
docs/4/docs/0/url	Old http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=P7-RC-2011-75&language=EN New http://www.europarl.europa.eu/doceo/document/RC-7-2011-0075_EN.html
docs/5/docs/0/url	Old http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B7-2011-6&language=EN New http://www.europarl.europa.eu/doceo/document/B-7-2011-0006_EN.html
docs/6/body	EC
events/2/docs/0/url	Old http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2011-39 New http://www.europarl.europa.eu/doceo/document/TA-7-2011-0039_EN.html

2019-07-06Show (11) Changes | Timetravel

activities	date: 2011-02-02T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20110202&type=CRE type: Debate in Parliament title: Debate in Parliament body: EP type: Debate in Parliament date: 2011-02-03T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=19540&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2011-39 type: Decision by Parliament, 1st reading/single reading title: T7-0039/2011 body: EP type: Results of vote in Parliament
committees
docs	date: 2011-01-26T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B7-2011-75&language=EN title: B7-0075/2011 type: Motion for a resolution body: EP date: 2011-01-26T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B7-2011-76&language=EN title: B7-0076/2011 type: Motion for a resolution body: EP date: 2011-01-26T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B7-2011-86&language=EN title: B7-0086/2011 type: Motion for a resolution body: EP date: 2011-01-26T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B7-2011-89&language=EN title: B7-0089/2011 type: Motion for a resolution body: EP date: 2011-01-26T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=P7-RC-2011-75&language=EN title: RC-B7-0075/2011 type: Joint motion for resolution date: 2011-02-02T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B7-2011-6&language=EN title: B7-0006/2011 type: Oral question/interpellation by Parliament body: EP date: 2011-06-17T00:00:00 docs: url: /oeil/spdoc.do?i=19540&j=0&l=en title: SP(2011)3791 type: Commission response to text adopted in plenary
events	date: 2011-02-02T00:00:00 type: Debate in Parliament body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20110202&type=CRE title: Debate in Parliament summary: O-0203/2010 date: 2011-02-03T00:00:00 type: Results of vote in Parliament body: EP docs: url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=19540&l=en title: Results of vote in Parliament date: 2011-02-03T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2011-39 title: T7-0039/2011 summary: Following the debate which took place during the sitting of 2 February 2011, the European Parliament adopted by 578 votes to 9 with 52 abstentions a resolution on the Tuberculosis Vaccine Initiative (TBVI) – practical implementation of the Europe 2020 strategy with a view to meeting MDG 6 and eliminating tuberculosis by 2050. The resolution had been tabled by the EPP, ALDE, S&D, ECR and Greens/ALE groups. It notes that with four years to go until the MDG deadline, the incidence of tuberculosis remains one of the main causes of death in the world, with nearly 2 million people dying as a result of the disease every year. Members underline the fact that only a vaccination programme involving a large-scale vaccination campaign could have a positive impact in terms of achieving MDG 6 after 2015, and in particular the eradication of tuberculosis by 2050. They consider vaccines to be an essential means of combating tuberculosis, together with better – reliable, low-cost and soundly based – testing, as well as more effective diagnosis and treatment, and this implies a major shift in the focus of research and an increase in sustainable funding. Tuberculosis vaccination ought to be carried out as a priority in dispensaries and clinics in developing countries. Members call, accordingly, for public health care services to be restored, taking the view that EU assistance should, first and foremost, support developing countries’ internal efforts to build human, institutional and infrastructure capacity. On the question of funding, Parliament notes that the objective is still to invest 3% of GDP in research and development in spite of budgetary constraints (COM(2010)2020 and COM(2010)0546), and it calls on the Commission to explore innovative funding channels , such as the establishment by the Member States and/or the Union of a financial guarantee to enable funding for the TBVI to be obtained from the European Investment Bank, with a view to securing finance for research in developing countries into neglected diseases and those involving little profit potential. Members point out that killer diseases such as tuberculosis ought to be the focus of a much greater pharmaceutical research effort, and insufficient research is currently being conducted into the most neglected diseases, which affect only people in developing countries. They call on the Commission and the Member States to stand by their funding commitments and do everything necessary to ensure that funds allocated to health care also reach the most impoverished people in developing countries, stressing the urgent need for public health services in the most remote areas. Lastly, Parliament considers that the success of ‘vertical’ funds to tackle specific diseases such as Aids, malaria and tuberculosis must not mean a siphoning-off of resources from so-called ‘horizontal’ basic health care infrastructure. It stresses that an integrated approach, covering the various programmes targeted at specific diseases such as AIDS, malaria and tuberculosis together with a consolidation of basic health care systems, would enable the needs of people in developing countries to be addressed. date: 2011-02-03T00:00:00 type: End of procedure in Parliament body: EP
links
other
procedure/legal_basis/0	Rules of Procedure EP 128-p5
procedure/legal_basis/0	Rules of Procedure of the European Parliament EP 128-p5
procedure/subject	Old 4.20.01 Medicine, diseases 4.20.02 Medical research 6.30 Development cooperation New 4.20.01 Medicine, diseases 4.20.02 Medical research 6.30 Development cooperation
procedure/subtype	Old Debate or resolution on oral questions New Debate or resolution on oral question/interpellation
procedure/title	Old Resolution on the Tuberculosis Vaccine Initiative (TBVI) - practical implementation of the Europe 2020 strategy with a view to meeting MDG 6 and eliminating tuberculosis by 2050 New Resolution on the Tuberculosis Vaccine Initiative (TBVI) - practical implementation of the Europe 2020 strategy with a view to meeting MDG 6 and eliminating tuberculosis by 2050

2014-11-10Show (5) Changes

activities	date: 2011-02-02T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20110202&type=CRE type: Debate in Parliament title: Debate in Parliament body: EP type: Debate in Parliament date: 2011-02-03T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=19540&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2011-39 type: Decision by Parliament, 1st reading/single reading title: T7-0039/2011 body: EP type: Results of vote in Parliament
committees
links
other
procedure	reference 2010/3016(RSP) title Resolution on the Tuberculosis Vaccine Initiative (TBVI) - practical implementation of the Europe 2020 strategy with a view to meeting MDG 6 and eliminating tuberculosis by 2050 legal_basis Rules of Procedure of the European Parliament EP 128-p5 stage_reached Procedure completed subtype Debate or resolution on oral questions type RSP - Resolutions on topical subjects subject 4.20.01 Medicine, diseases 4.20.02 Medical research 6.30 Development cooperation

Progress: Procedure completed

Legal Basis:

Subjects

Links

Events

Documents

Activities

History

ParlTrack - 2011-2024